An international study reports that the combination of two drugs could significantly retard the development of a dangerous form of prostate cancer in men who have specific mutations in DNA repair genes.

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor growth and slow symptom advance.

Prostate cancer is the second-leading cause of death in American men. However, prostate cancer is curable, thanks to options such as CyberKnife radiation therapy.

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL researchers.

Multidisciplinary teams, including various healthcare professionals, are essential for optimal prostate cancer care. Patients with prostate cancer can position themselves to receive the best care possible by being seen by a multidisciplinary team of healthcare providers.

In his new role as cancer center director at the Sanford Burnham Prebys medical research institute in La Jolla, Paul Boutros is hoping to use the opportunity to enable the center to — as he puts it, drawing on his Canadian background — “go where the puck is going, not where it is.”

Patients with a certain form of aggressive prostate cancer could benefit from a new combination of drugs which slow cancer growth, according to a new study.